SION
Sionna TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SION
Sionna Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing therapeutics for cystic fibrosis
21 Hickory Drive, Suite 500, Waltham, MA 02451
--
Sionna Therapeutics, Inc., was incorporated under the laws of the State of Delaware in August 2019. The company is a clinical-stage biopharmaceutical company whose mission is to revolutionize the current treatment model for cystic fibrosis patients by developing new drugs that normalize the function of cystic fibrosis transmembrane conductance regulator proteins and provide clinically meaningful benefits to patients with CF.
Company Financials
EPS
SION has released its 2025 Q3 earnings. EPS was reported at -0.46, versus the expected -0.49, beating expectations. The chart below visualizes how SION has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
